Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patients
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials / Casadei Gardini A, Frassineti GL, Foschi FG, Ercolani G, Ulivi P.. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - ELETTRONICO. - 49:(2017), pp. 943-944. [10.1016/j.dld.2017.04.022]
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.
Ercolani GSupervision
;Ulivi P.Data Curation
2017
Abstract
Different treatment strategy based on tumor etiology. Future studies should be made to evaluate if the use of first line regorafenib in HBV-positive HCC patients may be the best strategy for improvement the outcome of these patientsFile in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
